|
|
|||||||||||||||||||||||||
|
Genetic Technologies Ltd. (GENE) Genetic Technologies is a molecular diagnostics company that provides predictive testing and assessment tools to help physicians manage women's health. Co.'s key product, BREVAGenplus, was a clinically validated risk assessment test for non-hereditary breast cancer. Co. has launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. Co. has developed two new cancer risk assessment tests branded as GeneType for Colorectal Cancer and GeneType for Breast Cancer. Co. also develops other risk assessment tests across a range of diseases, including cardiovascular disease, type 2 diabetes, prostate cancer and melanoma.
|
|
|||||||||||||||||||||||||
Free GENE Email Alerts:
Genetic Technologies Ltd. (GENE) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.